BR0012467A - Agente terapêutico para hipercalcemia resistente à droga - Google Patents

Agente terapêutico para hipercalcemia resistente à droga

Info

Publication number
BR0012467A
BR0012467A BR0012467-2A BR0012467A BR0012467A BR 0012467 A BR0012467 A BR 0012467A BR 0012467 A BR0012467 A BR 0012467A BR 0012467 A BR0012467 A BR 0012467A
Authority
BR
Brazil
Prior art keywords
therapeutic agent
drug
resistant hypercalcemia
hypercalcemia
resistant
Prior art date
Application number
BR0012467-2A
Other languages
English (en)
Inventor
Hidemi Saito
Toshiaki Tsunenari
Etsuro Onuma
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR0012467A publication Critical patent/BR0012467A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"AGENTE TERAPêUTICO PARA HIPERCALCEMIA RESISTENTE à DROGA". A presente invenção refere-se a um agente terapêutico para hipercalcemia resistente à droga. O agente terapêutico compreende, como um ingrediente ativo, uma substância capaz de inibir a ligação entre uma proteína relacionada com o hormónio da paratireóide ( PTHrP ) e um receptor deste.
BR0012467-2A 1999-07-06 2000-07-06 Agente terapêutico para hipercalcemia resistente à droga BR0012467A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19227099 1999-07-06
PCT/JP2000/004523 WO2001002012A1 (fr) 1999-07-06 2000-07-06 Remedes contre l'hypercalcemie chimio-resistante

Publications (1)

Publication Number Publication Date
BR0012467A true BR0012467A (pt) 2002-06-11

Family

ID=16288493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012467-2A BR0012467A (pt) 1999-07-06 2000-07-06 Agente terapêutico para hipercalcemia resistente à droga

Country Status (17)

Country Link
EP (1) EP1195164A4 (pt)
KR (1) KR20020040743A (pt)
CN (1) CN1399557A (pt)
AR (1) AR020867A1 (pt)
AU (1) AU5849700A (pt)
BR (1) BR0012467A (pt)
CA (1) CA2373945A1 (pt)
CZ (1) CZ20014730A3 (pt)
HK (1) HK1046235A1 (pt)
HU (1) HUP0202218A3 (pt)
MX (1) MXPA02000018A (pt)
NO (1) NO20020044L (pt)
PL (1) PL353407A1 (pt)
RU (1) RU2002102916A (pt)
SK (1) SK162002A3 (pt)
WO (1) WO2001002012A1 (pt)
ZA (1) ZA200200264B (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02207099A (ja) * 1989-02-07 1990-08-16 Tonen Corp ＰＴＨｒＰ関連ペプチド、その製造法及び用途
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
JPH04228089A (ja) * 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
CA2087190A1 (en) * 1990-07-13 1992-01-14 Fred E. Cohen Parathyroid hormone analogues modified at positions
ATE287898T1 (de) * 1991-04-05 2005-02-15 Gen Hospital Corp Parathyroid-hormon-rezeptor und seine kodierende dna
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
JP3504697B2 (ja) * 1993-09-30 2004-03-08 株式会社先端生命科学研究所 ＰＴＨｒＰアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
CA2219361C (en) * 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
SK40599A3 (en) * 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
JP4372240B2 (ja) * 1997-05-15 2009-11-25 中外製薬株式会社 悪液質治療剤
PL345117A1 (en) * 1998-06-26 2001-12-03 Chugai Pharmaceutical Co Ltd Remedies for hypercalcemic crisis
TWI255718B (en) * 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration

Also Published As

Publication number Publication date
AU5849700A (en) 2001-01-22
CA2373945A1 (en) 2001-01-11
SK162002A3 (en) 2002-06-04
EP1195164A4 (en) 2005-09-28
CZ20014730A3 (cs) 2002-04-17
NO20020044D0 (no) 2002-01-04
HK1046235A1 (en) 2003-01-03
PL353407A1 (en) 2003-11-17
MXPA02000018A (es) 2003-07-21
EP1195164A1 (en) 2002-04-10
HUP0202218A2 (en) 2002-10-28
WO2001002012A1 (fr) 2001-01-11
WO2001002012A8 (fr) 2002-06-06
HUP0202218A3 (en) 2005-01-28
KR20020040743A (ko) 2002-05-30
CN1399557A (zh) 2003-02-26
ZA200200264B (en) 2003-04-30
NO20020044L (no) 2002-03-01
RU2002102916A (ru) 2003-11-10
AR020867A1 (es) 2002-05-29

Similar Documents

Publication Publication Date Title
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
BR0313627A (pt) Formulações farmacêuticas, processos para a preparação de formulação farmacêutica e método para o tratamento de dores
BR9811094A (pt) Agente terapêutico para tumores linfáticos
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
DK1123120T3 (da) Medicinsk aerosolformulering
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
BR9912223A (pt) Agente terapêutico para crise hipercalcêmica
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
BR9816013A (pt) Proteìna de ligação de interleucina-18
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
EP0861663A3 (en) Osteoclastgenic inhibitory agent comprising interleukin-18
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
NO985571L (no) Legemiddel for autoimmunsykdommer
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
BR9810433A (pt) Composições anti-helmìnticas
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.